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In recent years, it has been proposed that the suppression of apop-
tosis following a cytotoxic insult may represent a key determinant
of poor chemotherapeutic response (Dive and Hickman, 1991).
Foremost among the proteins thought to be involved is the BCL-2
family of pro-apoptotic (e.g. BAX, BCL-Xs, BAK, BAD, BIK,
BID) or anti-apoptotic (e.g. BCL-2, BCL-XL, MCL-1, BCL-W)
members (reviewed in Reed, 1997).
As part of our platinum drug discovery programme, we have
established panels of human ovarian carcinoma cell lines, sensi-
tive and resistant to cisplatin and analogues (Kelland et al, 1992a;
Holford et al, 1998). Furthermore, for many of the cell lines,
xenograft counterparts have been established (Kelland et al,
1992b). The aim of this study was to determine whether the levels
of proteins of the BCL-2 family may correlate with the platinum
drug sensitivity and resistance of these ovarian cell lines and
xenografts. In addition, as a further test of the role of Bcl-2 family
proteins in determining ovarian cancer cell line platinum drug
sensitivity, one sensitive cell line (A2780) has been transfected
with Bcl-2 and one (CH1) with BclxL. Furthermore, two resistant
lines (SKOV3 and A2780cisR) have been transfected with bax and
chemosensitivity patterns to both DNA-interactive and tubulin-
interactive anticancer drugs determined.
MATERIALS AND METHODS
Cell lines
A panel of parental human ovarian carcinoma cell lines were used
in this study – (A2780, CH1, 41M, LK1, LK2, PXN94, PA1,
OVCAR3, OAW42, SKOV3, 59M and OV1P) and lines made
resistant to cisplatin and other platinum analogues (A2780cisR,
ZD0473R, JM149R, JM335R; CH1cisR, JM216R, ZD0473R,
JM118R, JM149R, JM221R, JM335R; 41 McisR, JM216R,
JM221R; OVCAR3 carboR; OV1PcisR, PXN94tetraR). Parent
and platinum drug resistant lines have been previously described
(Kelland et al, 1992a, 1992b; Holford et al, 1998).
Transfections were performed using lipofectamine (Life
Technologies). Full-length cDNAs and/or vectors for bcl-2, bax
and bclXL were kindly supplied by Professor D Kerr (Birmingham,
UK), Dr S Korsmeyer (St Louis, MO, USA) and Dr G Nunez (Ann
Arbor, MI, USA) respectively. A2780 was stably transfected with
full-length bcl-2 cDNA using SV-40 as the promoter, and selection
by resistance to neomycin. A2780cisR and SKOV-3 lines were
transfected with a construct of full-length human bax coupled to an
HA tag cloned into the bicistronic plasmid vector pIRES-P
(EMBL:Z75185) under the control of the cytomegalovirus pro-
moter, or with an empty vector as control, using selection with
puromycin. CH1 is a relatively cisplatin sensitive cell line and was
transfected with Bclxl using the bicistronic vector pIRES-P or an
empty vector and selected for resistance to puromycin. In all cases,
expression of the transfected gene and resulting protein was
confirmed by immunoblotting (see below).
All cell lines were grown as monolayers in Dulbecco’s modified
Eagle medium (DMEM) supplemented with 10% fetal calf serum
(FCS; Imperial Laboratories, Andover, UK), 2 mML -glutamine
and 0.5 mg ml–1 hydrocortisone in a humidified 6% carbon
dioxide, 94% air atmosphere.
Human ovarian xenografts models used in the study were CH1,
CH1 cisR, PXN87, PXN871 (Iproplatin resistant), PXN95,
PXN951, PXN65, PXN100, SKOV3 and HX62 (Kelland et al,
1992b; Jones et al, 1993). These were grown in the flanks of nude
mice and routinely passaged on after reaching around 12 mm in
size.
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Platinum drugs were synthesized by Johnson Matthey Technology
Centre (Reading, Berkshire, UK) or AnorMED (Langley, BC,
Canada). Structures of platinum agents have been published
previously (Kelland et al, 1992a, 1992b; Holford et al, 1998).
Doxorubicin, etoposide and paclitaxel were obtained through the
Royal Marsden NHS Trust Hospital Pharmacy. All other chemi-
cals were obtained from Sigma Chemicals (Poole, UK) unless
otherwise stated.
Cytotoxicity assays
Sulphorhodamine B (SRB) and microtetrazolium (MTT) growth
inhibition assays were performed to assess chemosensitivity as
described previously (Kelland et al, 1992a). Unless otherwise indi-
cated, drug exposure was continuous for 96 h. For clonogenic
survival assays, 1000 cells of A2780BCL-2 and A2780 vector
(neo) cell lines were allowed to attach overnight in triplicate T25
flasks. Cisplatin exposure was for 2 h. After 7 days, colonies with
>50 cells were stained with methylene blue and counted.
Rate of apoptosis
This was determined by measuring cellular detachment from the
monolayer following drug exposure as described previously
(Ormerod et al, 1996).
Western blotting
This was performed as described previously using sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) separa-
tion and transfer to nitrocellulose membranes and visualization by
enhanced chemiluminescence reagents (ECL) (Holford et al,
1998). Semiquantitative levels were determined by scanning
densitometry and analysis by Imagequant software. Densitometric
levels were adjusted to a control level from one line for the ovarian
cell lines and another line for the xenografts. Antibodies used for
detection were BCL-2 (DAKO), BAX (Santa Cruz N-20), BCLXL
(Santa Cruz S-18), BAK (Calbiochem-AB-1), p21 (Santa-Cruz C-
19) and p53 (Santa Cruz DO-1).
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Figure 1 Relationships between sensitivity to cisplatin and protein levels of (A) BCL-2, (B) BAX, (C) BCLXL and (D) BAK for 12 human ovarian carcinoma cell
lines (1 = OVCAR-3, 2 = 59 M, 3 = SKOV-3, 4 = OVIP, 5 = PXN94, 6 = OAW42, 7 = PA1, 8 = LK1, 9 = LK2, 10 = A2780, 11 = CH1 and 12 = 41 M)Statistical analyses
When appropriate, statistical significance was tested using a two-
tailed Student’s t-test; a P-value of ≤0.05 was considered as signif-
icant. All values shown are means with the corresponding standard
error of the mean. Correlation analyses were determined by linear
regression or by Spearman rank and performed using GraphPad
Prism Software.
RESULTS
Characterization of BCL-2 family protein levels in
human ovarian cell lines and xenografts
Levels of BCL-2, BAX, BCLxL and BAK in our panel of 12
parental human ovarian cell lines as measured by Western blotting
and subsequent densitometry are presented in Figure 1A–D
respectively and related to sensitivity to cisplatin. The densito-
metric levels may be divided into three bands; < 10 equals absent
or very low levels; 10–60 represents low to moderate levels; and
levels above 60 represent moderate to high levels. Levels of BCL-
2 appeared inversely related to cisplatin sensitivity; many of the
resistant cell lines such as SKOV-3, 59M, OVCAR-3 possessed
relatively low levels while high levels were observed in the
cisplatin sensitive lines 41M and CH1. Spearman rank correlation
analysis revealed a significant inverse relationship between sensi-
tivity and BCL-2 levels (r = –0.81; P = 0.0022). There was no
significant relationship between the level of any of the remaining
proteins and the 96-h IC50 mM to cisplatin in the cell lines 
(BAX  r = –0.32; BCLXL r = 0.47; BAK r = –0.17).
BCL-2 protein levels in acquired platinum drug-resistant cell
lines showed no consistent pattern (data not shown). For example,
in the CH1 (and OVCAR-3) cell lines, platinum- and platinum
analogue-resistant cell lines had higher levels of BCL-2 protein
(1.1- to 2.2-fold), but in the 41M (and OV1P and PXN94) lines,
the platinum-resistant lines had significantly lower levels
(0.22–0.49). Interestingly, in the A2780 cell lines BCL-2 was
undetectable in the parent and cisR lines, but in the
A2780/ZD0473 R line the levels were significantly higher.
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Table 1 BCL-2 family protein levels in a panel of 12 human ovarian
carcinoma xenografts of differing responsiveness to platinum drugs
BCL-2 BAX BCL-XL BAK Growth Tumour
protein protein protein protein delayb volume
(units) (units) (units) (units) (days) doubling
timec (days)
PXN/65 11.5 80 118.6 75.1 >238 19.0
PXN/100 3.0 100 142.6 85 >259 11.5
PXN87 ND 55.9 ND 150 180 12.1
PXN87Ia ND 12.3 ND 135.3 15.0 12
CH1 35.8 90.8 154.9 60.4 29.2 4.7
CH1cisR 44.4 176.4 115.1 88.8 10.4 3.6
HX110 98.2 44.5 47.9 229.3 41.7 3.8
HX110P+ 59.7 9.8 28.5 80.7 6.5 8.0
PXN95 ND 19.1 ND 371.4 81 17.7
PXN95I+ ND 12.7 ND 193.4 11.5 8.5
HX62 ND 50 70.2 104.2 0.5 4.5
SKOV-3 4.9 55 86.6 185.4 10.7 6.2
aP = carboplatin resistant; I = iproplatin resistant. b,cGrowth delay to cisplatin
(weekly intraperitoneal dosing for 4 weeks; 4–8 mg kg–1) and tumour doubling
time values taken from Kelland et al (1992a, b) and Jones et al (1993).
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Figure 2 Sensitivity of A2780 vector (neo) control and A2780BCL-2
transfect to cisplatin by (A) MTT (vector control = open bars; A2780BCL2
transfect solid bars) or SRB assay (vector control = dotted bars; A2780BCL2
transfect cross-hatched bars) at 48, 72 or 96 h post-drug exposure or (B)
clonogenic cell survival assay following 2 h exposure to cisplatin for A2780
vector (neo) control (n n) or A2780BCL-2 transfect (s) or (C) induction of
apoptosis as measured by cellular detachment following 2 h exposure to
cisplatin for A2780 vector (neo) control (n n) or A2780BCL-2 transfect (s).
* denotes statistical significance (P < 0.05)BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma 439
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Levels of the BCL-2 family proteins in a panel of human
ovarian carcinoma xenografts of varying responsivenesss to
cisplatin are shown in Table 1. Spearman correlation analysis
showed no significant correlation (P > 0.05) between responsive-
ness to cisplatin (growth delay) and levels of BCL2, BAX, BCLXL
or BAK. As with the pairs of in vitro cell lines, there was no
consistent pattern in protein levels.
Characterization of an A2780 BCL-2 stable transfected
line
The A2780BCL-2 line, in contrast to the vector control, was
shown to have enhanced expression of the BCL-2 protein (data not
shown), similar doubling times (21.1 ± 0.9 h and 20.1 ± 1.1 h
respectively) and similar levels of platinum accumulation and
DNA platination following exposure to cisplatin (data not shown).
The sensitivity of the A2780 vector (neo) control and BCL-2
transfect to cisplatin was determined by 3 independent assays
(MTT, SRB – Figure 2A; and clonogenic – Figure 2B) and, for the
short-term colourimetric assays at 48-, 72- and 96-h post-drug
exposure. Figure 2A reveals an interesting pattern of relative
response vs time of assay. Whereas at 48 and 72 h post-drug expo-
sure the BCL-2-transfected line was more resistant to cisplatin
than the vector control, at 96 h the reverse was true with the BCL-
2 line being significantly more sensitive than the vector control by
both assays. Results of a colony forming assay (Figure 2B)
showed no significant difference in sensitivity between the lines.
Results using the 96 h SRB growth inhibition assay for a range of
platinum and other standard antitcancer agents of diverse mecha-
nisms of action (e.g. topoisomerase I and II inhibitors, tubulin
interactive drugs) showed a tendency in all cases for the
A2780BCL-2 transfect to be more sensitive than the vector control
although this only reached statistical significance in the cases of
cisplatin and the topoisomerase I inhibitor camptothecin (data not
shown).
The rate of cellular detachment following exposure to 10 mM
cisplatin for 2 h was used an indicator of apoptosis in these cell
lines (Ormerod et al, 1996). Results are shown in Figure 2C. At 
48 h post-exposure, there was greater detachment with the vector
control line (11.1 ± 2.6% vs 6.0 ± 0.41% in A2780BCL-2).
However, by 96 h, the trend was in the opposite direction 
(38.3  ± 2.7% in vector control vs 47.5 ± 3.8% in A2780BCL-2).
Following exposure to 25 mM cisplatin (5 times the IC50) for 2 h,
in the A2780BCL-2 transfect there was induction of BCL-2, BAX
and BAK, some induction of p53 and p21 but no marked induction
of BCLXL. In contrast, the most notable differences for the vector
control were: (1) a decrease in the level of BAK, (2) no induction
of BCL-2, and (3) greater induction of p53 and p21. The responses
of the BAX and BCLXL proteins were similar in both lines (data
not shown).
Characterization of A2780cisR and SKOV-3 bax
transfects and CH1 BCLXL transfect
BAX protein levels were 1.4-fold higher in A2780cisR and sixfold
higher in SKOV3 transfects when compared to vector controls.
The sensitivity of the transfected lines as measured by the 96-h
SRB cytotoxicity assay to four DNA-interactive agents (cisplatin,
ZD0473, doxorubicin and etoposide) and four tubulin-interactive
agents (paclitaxel, docetaxel, vinblastine and colchicine) showed
that there were no significant differences in sensitivity within the
two cell line pairs to any of the drugs evaluated.
BCLXL levels were fourfold higher in the CH1-transfected line
compared with the vector control. The 96-h SRB cytotoxicity
assay results showed a significant increase in resistance in the
transfected line compared with the control for ZD0473 alone (IC50
in mM of 0.6 ± 0.08 for CH1puro and 1.53 ± 0.4 for CH1BCLXL;
RF 2.56, P = 0.05), although the parental non-transfected CH1 line
showed a similar sensitivity to that of the BCLXL transfect. For all
of the remaining drugs there was no significant difference in sensi-
tivity between the two isogenic BCLXL lines (e.g. cisplatin IC50 in
mM of 0.201 ± 0.04 for CH1puro and 0.26 ± 0.02 for CH1BCLXL;
RF 1.3) (remaining data not shown).
DISCUSSION
This study has addressed the possible role of BCL-2 and three
other commonly described members, two pro-apoptotic (BAX and
BAK) and one other anti-apoptotic (BCLXL) in determining the
cisplatin sensitivity of panels of human ovarian carcinoma cell
lines and xenografts. The major findings from this study were: (1)
overexpression of BCL-2 protein in human ovarian carcinoma cell
lines, either naturally or via stable gene transfection, tended to
confer sensitivity to cisplatin rather than resistance. A statistically
significant inverse correlation (r of – 0.81) was observed between
BCL-2 levels and cisplatin sensitivity in 12 parental ovarian cell
lines and transfection of Bcl-2 into A2780 cells conferred a signi-
ficant increase in sensitivity to cisplatin (and the topoisomerase I
inhibitor camptothecin) when using a 96 h growth inhibition
assay; (2) no significant correlations were obtained when
comparing in vitro drug sensitivity to levels of BAX, BCLXL or
BAK or when comparing levels of all four proteins to the platinum
response of 12 ovarian cancer xenografts; (3) introduction of Bax
into relatively cisplatin resistant lines or BCLXL into a relatively
sensitive line did not confer marked changes in chemosensitivity.
Our in vitro results with BCL2 in ovarian cancer differ to many
other in vitro studies, especially using cells of haematopoietic
origin. Herein, overexpression has been shown to promote cell
survival by inhibiting apoptosis induced by a variety of stimuli
including chemotherapeutic agents (reviewed in Reed, 1997).
However, two other independent studies also using human epithe-
lial cells (HeLa) and exposure to either aphidicolin or etoposide
have shown an inhibition of apoptosis through overexpression of
bcl-2 but no difference in clonogenic cell survival (Yin and
Schimke, 1995; Lock and Stribinskiene, 1996). Hence these data
agree more closely with our findings where we observed less
apoptosis and low level resistance conferred by overexpression of
BCL-2 in A2780 cells at 48 h post-treatment, the opposite at 96 h
and no difference in clonogenic cell survival. Interestingly, with
respect to ovarian cancer, transfection of bcl-2 into A2780 cells
caused low level (2.1- to 3.5-fold) cisplatin resistance but in this
study, growth inhibition was assessed (by MTT assay) at only 48 h
post-cisplatin treatment (Eliopoulos et al, 1995; Herod et al, 1996).
Results from longer term or colony forming assays were not
reported. Clinically, in lymphoma, neuroblastoma and leukaemia
the overexpression of BCL-2 is associated with an inferior
prognosis (reviewed in Reed, 1997). However, in breast, non-440 PJ Beale et al
British Journal of Cancer (2000) 82(2), 436–440 © 2000 Cancer Research Campaign
small-cell lung, renal cell, colon and ovarian carcinoma higher
expression of BCL-2 is associated with a better outcome (e.g.
Herod et al, 1996).
There was no consistent pattern of BCL-2 expression across
various acquired platinum drug-resistant lines, the most notable
change being increased expression in a subline possessing resis-
tance to ZD0473 (AMD473), a sterically hindered platinum drug
now in phase I trial (Holford et al, 1998). However, it is unclear to
what extent, if any, the BCL-2 overexpression contributes to the
acquired resistant phenotype in this line. We observed a differen-
tial induction of BAK following cisplatin exposure in the A2780
vector control versus BCL-2 transfect with marked induction in
the presence of BCL-2 overexpression compared to a reduction in
levels of this pro-apoptotic protein in the vector control. Thus, up-
regulation of BAK may contribute to the enhanced sensitivity of
the BCL-2-transfected line to cisplatin observed by 4-day growth
inhibition assays. Also when using A2780 cells, an up-regulation
of BAK (and BAX) was observed following paclitaxel or cisplatin
treatment (Jones et al, 1998).
Overall, our results suggest that, at least in human ovarian carci-
noma cell lines, high BCL-2 levels (either naturally occurring or
through gene transfection) confers a trend towards sensitivity not
resistance to platinum drugs.
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